Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Joseph Bisaha, David Jackson

Premium

Arno Therapeutics has appointed Joseph Bisaha as its new VP of clinical operations and project management and David Jackson as its VP of diagnostics. In their new positions, both Bisaha and Jackson will support the development of the personalized cancer drug onapristone, Arno's lead product.

Before joining Arno, Bisaha was a clinical research consultant with Kaizen Clinical Services, where he handled Arno's clinical Operations and project management activities. During his 17-year career, he has held various management roles, including associate VP of project management at ImClone Systems and senior director of clinical research and drug development at Ono Pharma.

Jackson comes to Arno from molecular testing firm PrimeraDx where he was VP of business development. Jackson also was senior director of companion diagnostic partnerships at Qiagen Manchester and consulted drug and diagnostics developers on the development and commercialization of personalized medicines and companion tests.

Filed under

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.